drugset
drugset / Trial / NCT06769620

A First in Human Study of ORT247 in Healthy Volunteers

NCT06769620 ↗

Phase 1 Completed 44 enrolled Orthogonal Neuroscience Inc.
RandomizedSequentialTriple-blindTreatment

Summary

This is a single center, double-blinded, randomized, placebo controlled single ascending dose clinical study, with the primary purpose of evaluating the safety, tolerability, pharmacokinetics (PK), and immunohistochemistry of escalating intravenous doses of ORT247 in healthy volunteers.

Timeline

Start
2022-06-06
Primary completion
2023-10-24
Completion
2023-10-24

Drugs

EvaluationDrugModalityDoseRoute
Subject ORT247 Unknown 75 mg Intravenous
Subject ORT247 Unknown 150 mg Intravenous
Subject ORT247 Unknown 300 mg Intravenous
Subject ORT247 Unknown 600 mg Intravenous
Subject ORT247 Unknown 1200 mg Intravenous

Indications

amyotrophic lateral sclerosis